Twist Bioscience Corporation (NASDAQ:TWST) Stock Has Average Target Price of $143.67 According to Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $143.67.

TWST has been the subject of a number of recent research reports. Piper Sandler boosted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Robert W. Baird increased their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, Canaccord Genuity Group raised their price objective on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, October 12th.

Twist Bioscience Price Performance

NASDAQ TWST opened at $139.77 on Tuesday. The business’s fifty day moving average is $148.39 and its 200 day moving average is $100.92. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a market capitalization of $8.76 billion, a PE ratio of -62.96 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. During the same quarter in the previous year, the company earned $0.33 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. Sell-side analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the sale, the insider directly owned 63,789 shares of the company’s stock, valued at $12,048,466.32. This trade represents a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the sale, the senior vice president directly owned 106,632 shares in the company, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 601,920 shares of company stock worth $93,768,202. 3.08% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Twist Bioscience in the 2nd quarter worth $600,191,000. William Blair Investment Management LLC purchased a new position in shares of Twist Bioscience during the second quarter valued at about $223,722,000. Bank of America Corp DE bought a new stake in shares of Twist Bioscience in the second quarter worth about $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience in the first quarter worth about $22,563,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Twist Bioscience in the second quarter worth about $19,722,000.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.